Market Eyes LiveJohnson & Johnson (JNJ) Stock Rating & Analysis
MELANY's data-driven read on Johnson & Johnson · Pharmaceutical Preparations.
Johnson & Johnson is the world's largest and most diverse healthcare company, organized into two divisions, innovative medicine and medtech, which represent all of its sales after the 2023 divestment of its consumer business, Kenvue. Following 2023-24 restructurings, its drug division focuses on immunology, oncology, and neurology, and just over half of total revenue is generated in the United States.
Why JNJ scores 60/100
MELANY scores Johnson & Johnson 60/100 by weighing eight factors. Here is how JNJ breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 21.2x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 68%
- ROE 26%
Direction and relative strength of the recent share-price trend.
- Price +5.2% above 50-day MA
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 3 of last 4 quarters
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for JNJ
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Johnson & Johnson sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds JNJ's momentum and catalyst factors above.
Tracking JNJ
Johnson & Johnson rates Hold right now, so MELANY is not flagging a fresh entry. Create a free account to add JNJ to your watchlist and get alerted the moment the rating changes.
How MELANY rates JNJ
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Johnson & Johnson's 60/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about JNJ
Is Johnson & Johnson (JNJ) a buy?
As of 2026-08-21, MELANY rated Johnson & Johnson Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Johnson & Johnson's MELANY score?
Johnson & Johnson (JNJ) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the JNJ stock rating calculated?
MELANY scores JNJ from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Johnson & Johnson stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Johnson & Johnson (JNJ) Hold with a composite of 60/100 as of 2026-08-21. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the JNJ stock price forecast?
MELANY does not publish price targets or forecasts for JNJ. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Johnson & Johnson, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is JNJ stock overvalued or undervalued?
MELANY's valuation factor currently reads 36/100 for Johnson & Johnson, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives JNJ's read.
What price should I buy JNJ at?
MELANY is not flagging a fresh entry for JNJ at its current Hold rating, so there is no entry zone to publish right now. Watchlisting JNJ in the free app gets you alerted the moment that changes.
What are the risks of buying JNJ stock?
The top risks MELANY currently flags for Johnson & Johnson: Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Johnson & Johnson a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 82/100 for Johnson & Johnson, and earnings track record, at 65/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will JNJ stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 73/100 for JNJ right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this JNJ rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-21. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores JNJ continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
JNJ's live rating and alerts are free either way. The app is our flagship.